SEC Form 4 · accession 0001159036-26-000096
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Ramsay
Officer — EVP, PRESIDENT, DRUG DELIVERY
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | M | 10,000 | $0.00 | A | 10,000 | D | |
| Common StockF1 | Jun 30, 2026 | F | 5,408 | $78.27 | D | 4,592 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jun 30, 2026 | M | 10,000 | D | — | — | Common Stock | 10,000 | 0 | D |
| Restricted Stock UnitsF3 | $0.00 | Jul 1, 2026 | A | 16,232 | A | Jul 1, 2027 | — | Common Stock | 16,232 | 16,232 | D |
| Option to Purchase Common StockF4 | $77.01 | Jul 1, 2026 | A | 39,823 | A | Jul 1, 2027 | Jul 1, 2036 | Common Stock | 39,823 | 39,823 | D |
Explanation of responses
- F1The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.
- F3This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
- F4This option vests one-fourth on such date and then 1/48th monthly thereafter.